Patents by Inventor Wenlang Fu

Wenlang Fu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230183214
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 15, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Brandon D. CASH, Wenlang FU, George Madalin GIAMBASU, Andrew M. HAIDLE, Brett A. HOPKINS, Matthew A. LARSEN, Charles A. LESBURG, Ping LIU, Meredeth A. MCGOWAN, Qinglin PU, Sulagna SANYAL, Phieng SILIPHAIVANH, Catherine M. WHITE, Xin YAN
  • Publication number: 20230147170
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 11, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. Hicks, Amjad Ali, John S. Debenham, Anthony Donofrio, Wenlang Fu, Ying-Duo Gao, Alan Hruza, Yeon-Hee Lim, Matthew J. Lombardo, Peter Nizner, Sung-Sau So, Zheng Tan, Daniel A. Tatosian, Dong Xiao, Dexi Yang, Yang Yu
  • Publication number: 20220235033
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: May 26, 2020
    Publication date: July 28, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, John S. Debenham, Amjad Ali, Lan Wei, Tianying Jian, Dexi Yang, Anthony K. Ogawa, Wenlang Fu, Matthew Lombardo, Rongze Kuang, Meng Yang, Sung-Sau So, Kenneth Ellsworth, Peter Nizner, Daniel A. Tatosian, Robert R. Wilkening, Jun Wang
  • Patent number: 10450335
    Abstract: Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 22, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wenlang Fu, Zhiqiang Guo, Ning Qi, Izzat T. Raheem, Petr Vachal, Ming Wang, John D. Schreier
  • Publication number: 20180362563
    Abstract: Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: December 12, 2016
    Publication date: December 20, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wenlang Fu, Zhiqiang Guo, Ning Qi, Izzat T. Raheem, Petr Vachal, Ming Wang, John D. Schreier
  • Patent number: 9512426
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: December 6, 2016
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Patent number: 9040691
    Abstract: This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: May 26, 2015
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jürgen Klar, Verena Vöhringer, Joachim Telser, Mario Lobell, Frank Süβmeier, Volkhart Min-Jian Li, Michael Böttger, Stefan Golz, Dieter Lang, Karl-Heinz Schlemmer, Thomas Schlange, Andreas Schall, Wenlang Fu
  • Publication number: 20150132761
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 14, 2015
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Patent number: 8877439
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: November 4, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Publication number: 20140256718
    Abstract: This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.
    Type: Application
    Filed: June 26, 2012
    Publication date: September 11, 2014
    Applicants: BAYER INTELLECTUAL PROPERTY GmbH, BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Jürgen Klar, Verena Vöhringer, Joachim Telser, Mario Lobell, Frank Süssmeier, Volkhart Min-Jian Li, Michael Böttger, Stefan Golz, Dieter Lang, Karl-Heinz Schlemmer, Thomas Schlange, Andreas Schall, Wenlang Fu
  • Patent number: 8338595
    Abstract: This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: December 25, 2012
    Assignee: Bayer HealthCare LLC
    Inventors: Julie A. Dixon, Catherine Brennan, Karl Miranda, Brent Chandler, Barton Phillips, Jianmei Fan, Michael Brands, Andrea McClure, Benjamin D. Jones, Wenlang Fu, Donald Bierer, Steven Magnuson, Harold C. E. Kluender
  • Publication number: 20120252027
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Application
    Filed: December 9, 2010
    Publication date: October 4, 2012
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Publication number: 20110195110
    Abstract: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.
    Type: Application
    Filed: December 1, 2006
    Publication date: August 11, 2011
    Inventors: Roger Smith, Holia N. Hatoum-Mokdad, Louis David Cantin, Donald E. Bierer, Wenlang Fu, Dhanapalan Nagarathnam, Gaetan Ladouceur, Yamin Wang, Herbert Ogutu, Scot Wilhelm, Ian Taylor, Sanjeeva Reddy, Richard Gedrich, Christopher Carter, Aaron Schmitt, Xiaomei Zhang
  • Publication number: 20110098301
    Abstract: Pyrimidine derivatives of formula pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.
    Type: Application
    Filed: March 9, 2006
    Publication date: April 28, 2011
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Julie A. Dixon, Dhanapalan Nagarathnam, Lei Zhang, Chunguang Wang, Lin Yi, Yuanwei Chen, Jianqing Chen, Brian R. Bear, Michael Brands, Alexander Hillisch, Donald Bierer, Ming Wang, Wenlang Fu
  • Publication number: 20100075958
    Abstract: This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.
    Type: Application
    Filed: July 20, 2009
    Publication date: March 25, 2010
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Julie A. Dixon, Catherine Brennan, Karl Miranda, Brent Chandler, Barton Phillips, Jianmei Fan, Michael Brands, Andrea McClure, Benjamin Jones, Wenlang Fu, Donald Bierer, Steven Magnuson, Harold C.E. Kluender
  • Publication number: 20100075967
    Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.
    Type: Application
    Filed: August 28, 2009
    Publication date: March 25, 2010
    Applicant: BAYER PHARMACEUTICALS CORPORATION
    Inventors: Julie A. Dixon, Dhanapalan Nagarathnam, Lei Zhang, Chunguang Wang, Lin Yi, Yuanwei Chen, Jianging Chen, Brian R. Bear, Michael Brands, Alexander Hillisch, Donald Bierer, Ming Wang, Wenlang Fu, Martin F. Hentemann, Ann-Marie Bullion, Manoj Patel
  • Patent number: 7678804
    Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 16, 2010
    Assignee: Bayer Healthcare LLC
    Inventors: Julie A. Dixon, Dhanapalan Nagarathnam, Lei Zhang, Chunguang Wang, Lin Yi, Yuanwei Chen, Jianqing Chen, Brian R. Bear, Michael Brands, Alexander Hillisch, Donald Bierer, Ming Wang, Wenlang Fu, Martin F. Hentemann, Ann-Marie Bullion, Manoj Patel
  • Publication number: 20090286785
    Abstract: This invention relates to novel compounds (I) and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.
    Type: Application
    Filed: April 7, 2006
    Publication date: November 19, 2009
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Dhanapalan Nagarathnam, Yuanwei Chen, Wenlang Fu, Donald Bierer, Ming Wang, Michael Brands, Yamin Wang, Brian R. Bear
  • Publication number: 20090258888
    Abstract: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.
    Type: Application
    Filed: April 7, 2006
    Publication date: October 15, 2009
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Dhanapalan Nagarathnam, Yuanwei Chen, Wenlang Fu, Donald Bierer, Ming Wang, Michael Brands, Yamin Wang, Brian R. Bear, Aaron Schmitt, Eric Mull, David Miller, Jin Zhao
  • Patent number: 7582645
    Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: September 1, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Julie A. Dixon, Dhanapalan Nagarathnam, Lei Zhang, Chunguang Wang, Lin Yi, Yuanwei Chen, Jianqing Chen, Brian Bear, Michael Brands, Alexander Hillisch, Donald Bierer, Ming Wang, Wenlang Fu, Martin F. Hentemann, Ann-Marie Bullion